All News

Five trials presented at AAAAI 2026 highlight new therapies and prevention strategies for hereditary angioedema, atopic dermatitis, asthma, and chronic urticaria.

Large study links DASH and other healthy diets

CROI 2026: Phase III data show once-daily Eslatravir/Ravin matches BFTAF in treatment‑naive HIV, achieving high viral suppression at 48 weeks.

Phase 3 FINE-ONE shows finerenone cuts protein in urine for type 1 diabetes CKD patients, with manageable safety, hinting at new kidney protection.

ATS: Replace race-based PFTs with race-neutral GLI Global equations to improve clinical equity and accuracy.

New FDA approvals span swallowable obesity balloon, dupilumab for fungal sinusitis, oral desmopressin, updated menopause labels, and sildenafil film.

How primary care tackles obesity stigma with lifestyle, GLP-1-based medications, and team-based care.

Maternal analgesic allergy labels tied to eclampsia and preterm birth; delabeling may improve perinatal outcomes.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

Learn how primary care spots early hearing loss, flags urgent red symptoms, and boosts hearing-aid use to protect cognition and quality of life.

ACP updates RSV vaccine guidance: adults 75+ get a one-time protein subunit shot; higher-risk ages 60–74 may consider it to prevent hospitalization.

HIV specialist Jürgen Rockstroh, MD, discusses the importance of PrEP being more accessible through primary care physicians.

New real-world evidence links GLP-1RAs to lower acute care use and fewer treatment escalations than topiramate for chronic migraine.

Review key updates to the Dietary Guidelines for Americans to support patient counseling, nutritional assessments, and evidence-based interventions.

75.5% of pediatric food-allergic patients possess multiple concurrent allergies across three distinct clinical clusters, underscoring the importance of expanded allergy screening.

GLP‑1 therapy reduces asthma flare-ups in overweight non‑diabetics, suggesting a promising add-on for obesity-related asthma care.

AAAAI 2026: In LIBERTY-CSU CUPID, dupilumab reduced ISS7 and UAS7 at 24 weeks across BMI, angioedema, and gender subgroups in CSU.